Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

John L. Marshall, MD
Published Online: Monday, Dec 04, 2017



John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

RAS signaling is very important for many GI cancers, but it is very complicated, says Marshall. There may be new treatments on the horizon, though, said Frank McCormick, PhD, FRS, who oversees the nation’s strategic initiative to develop RAS inhibitors.

If an effective RAS inhibitor is developed, it could revolutionize the treatment of GI cancer, says Marshall.
 


John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

RAS signaling is very important for many GI cancers, but it is very complicated, says Marshall. There may be new treatments on the horizon, though, said Frank McCormick, PhD, FRS, who oversees the nation’s strategic initiative to develop RAS inhibitors.

If an effective RAS inhibitor is developed, it could revolutionize the treatment of GI cancer, says Marshall.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x